{
    "ticker": "TSLH",
    "name": "Tessera Therapeutics, Inc.",
    "description": "Tessera Therapeutics, Inc. is a biotechnology company focused on developing gene therapies that leverage the power of the body's natural processes for the treatment of genetic diseases. Founded in 2018, Tessera is pioneering a new approach to gene therapy through its proprietary Gene Writing technology, which aims to precisely edit genes and modify genetic sequences in a safe and effective manner. The company's mission is to unlock the full potential of gene therapy by creating transformative treatments that can address underlying genetic causes of diseases rather than just their symptoms. Tessera's innovative platform allows for the targeted delivery of genetic materials, which can lead to more durable and effective therapeutic outcomes. Tessera is committed to advancing the science of gene therapy to improve the lives of patients with genetic disorders, and it actively collaborates with leading research institutions and industry partners to accelerate its development pipeline. The company is also focused on building a sustainable business model that prioritizes scientific integrity and patient-centric approaches in its research and development efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2018",
    "website": "https://www.tesseratherapeutics.com",
    "ceo": "Rafael F. Rangel",
    "social_media": {
        "twitter": "https://twitter.com/TesseraTx",
        "linkedin": "https://www.linkedin.com/company/tessera-therapeutics/"
    },
    "investor_relations": "https://ir.tesseratherapeutics.com",
    "key_executives": [
        {
            "name": "Rafael F. Rangel",
            "position": "CEO"
        },
        {
            "name": "Jennifer A. Doudna",
            "position": "Co-Founder and Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "Gene Writing Platform",
                "Therapeutic Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tessera Therapeutics, Inc. | Innovating Gene Therapy Solutions",
        "meta_description": "Explore Tessera Therapeutics, Inc., a biotechnology leader innovating in gene therapy with its Gene Writing technology. Discover our mission to transform genetic disease treatment.",
        "keywords": [
            "Tessera Therapeutics",
            "Gene Therapy",
            "Biotechnology",
            "Genetic Diseases",
            "Gene Editing"
        ]
    },
    "faq": [
        {
            "question": "What does Tessera Therapeutics specialize in?",
            "answer": "Tessera Therapeutics specializes in developing gene therapies focused on addressing genetic diseases."
        },
        {
            "question": "Who is the CEO of Tessera Therapeutics?",
            "answer": "Rafael F. Rangel is the CEO of Tessera Therapeutics, Inc."
        },
        {
            "question": "Where is Tessera Therapeutics headquartered?",
            "answer": "Tessera Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is the Gene Writing technology?",
            "answer": "Gene Writing technology is Tessera's proprietary platform that allows for precise editing and modification of genetic sequences."
        },
        {
            "question": "When was Tessera Therapeutics founded?",
            "answer": "Tessera Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "SGEN"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "BMY"
    ]
}